The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Global variation in copy number in the human genome
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W., et al. (2006) · Nature · doi:10.1038/nature05329 · Cited by 4,288
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
The International SNP Map Working Group, Laboratories:, C. S. H., Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., National Center for Biotechnology Information:, Marth, G., Sherry, S., et al. (2001) · Nature · doi:10.1038/35057149 · Cited by 2,977
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,346
Assessing the Generalizability of Prognostic Information
Justice, A. C., Covinsky, K. E., & Berlin, J. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00016 · Cited by 1,160
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series
Cardno, A. G., Marshall, E. J., Coid, B., Macdonald, A. M., Ribchester, T. R., Davies, N. J., Venturi, P., Jones, L. A., Lewis, S. W., Sham, P. C., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.162 · Cited by 797
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Jönsson, E. G., Nöthen, M. M., Grünhage, F., Farde, L., Nakashima, Y., Propping, P., & Sedvall, G. C. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000532 · Cited by 721
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Large-scale genotyping of complex DNA
Kennedy, G. C., Matsuzaki, H., Dong, S., Liu, W.-M., Huang, J., Liu, G., Su, X., Cao, M., Chen, W., Zhang, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt869 · Cited by 572
Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population
Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., Gunnarsdottir, S., Walker, N., Petursson, H., Crombie, C., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345442 · Cited by 559
Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004) · Human Mutation · doi:10.1002/humu.20039 · Cited by 510
A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.
Accili, D., Fishburn, C. S., Drago, J., Steiner, H., Lachowicz, J. E., Park, B. H., Gauda, E. B., Lee, E. J., Cool, M. H., Sibley, D. R., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1945 · Cited by 468
Arinami, T. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.4.577 · Cited by 455
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Glutamate receptor expression in schizophrenic brain
Meador-Woodruff, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00044-2 · Cited by 412
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 385
Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29199-0 · Cited by 357
Pharmacogenetic prediction of clozapine response
Arranz, M., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., Lesch, K., Meyer, J., Sham, P., Collier, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02221-2 · Cited by 347
Self-citationCauses and consequences of duration of untreated psychosis in schizophrenia
Drake, R. J., Haley, C. J., Akhtar, S., & Lewis, S. W. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.6.511 · Cited by 346
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Association between clozapine response and allelic variation in 5-HT2A receptor gene
Arranz, M. J., Collier, D. A., Sodhi, M., Ball, D., Roberts, G. W., Sham, P., Kerwin, R., Price, J., & Roberts, G. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92168-0 · Cited by 333
Self-citationde Leon, J., Susce, M. T., Pan, R.-M., Fairchild, M., Koch, W. H., & Wedlund, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0103 · Cited by 319
Self-citationAntipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
de Leon, J., Armstrong, S. C., & Cozza, K. L. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.1.75 · Cited by 300
Self-citationBertolino, A., Caforio, G., Blasi, G., De Candia, M., Latorre, V., Petruzzella, V., Altamura, M., Nappi, G., Papa, S., Callicott, J. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1798 · Cited by 289
Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance
Munro, J., O'Sullivan, D., Andrews, C., Arana, A., Mortimer, A., & Kerwin, R. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.6.576 · Cited by 285
Genetic basis of schizophrenia
McGuffin, P., Owen, M., & Farmer, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92285-7 · Cited by 275
Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs
Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K., & Sidhom, T. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0403 · Cited by 273
Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review
Spina, E., & De Leon, J. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00017.x · Cited by 271
Self-citationPharmacogenetics and drug development: the path to safer and more effective drugs
Roses, A. D. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1432 · Cited by 268
Templeman, L. A., Reynolds, G. P., Arranz, B., & San, L. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200504000-00002 · Cited by 267
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics
Boulton, D. W., DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01680-6 · Cited by 259
The –1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity
Parsons, M. J., D'Souza, U. M., Arranz, M.-J., Kerwin, R. W., & Makoff, A. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.020 · Cited by 258
Self-citationMeta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
Arranz, M. J., Munro, J., Sham, P., Kirov, G., Murray, R. M., Collier, D. A., & Kerwin, R. W. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00032-2 · Cited by 255
Self-citationWeiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253
Statistical Methods for Identifying Differentially Expressed Genes in DNA Microarrays
Storey, J. D., & Tibshirani, R. (2003) · Functional Genomics · doi:10.1385/1-59259-364-x:149 · Cited by 253
The genetic basis for schizophrenia
Shields, J., & Gottesman, I. I. (1973) · Cited by 247
Lerer, B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00293-2 · Cited by 241
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
Steen, V. M., Løvlie, R., MacEwan, T., & McCreadie, R. G. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000249 · Cited by 239
Lundstrom, K., & Turpin, M. P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1296 · Cited by 232
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
Eiermann, B., Engel, G., Johansson, I., Zanger, U. M., & Bertilsson, L. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.t01-1-00605.x · Cited by 227
The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis
Petronis, A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.005 · Cited by 225
Arranz, M. J., Munro, J., Owen, M. J., Spurlock, G., Sham, P. C., Zhao, J., Kirov, G., Collier, D. A., & Kerwin, R. W. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000348 · Cited by 220
Self-citationRing, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., & Wrighton, S. A. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12326-4 · Cited by 214
Basile, V. S., Masellis, M., McIntyre, R. S., Meltzer, H. Y., Lieberman, J. A., & Kennedy, J. L. (2001) · PubMed · Cited by 211
Lieberman, J. A., Koreen, A., Chakos, M., Sheitman, B., Woerner, M. G., Alvir, J. M. J., & Bilder, R. M. (1996) · PubMed · Cited by 211
Brockmöller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Müller‐Oerlinghausen, B., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127494 · Cited by 204
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
van der Weide, J., Steijns, L. S. W., van Weelden, M. J. M., & de Haan, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00002 · Cited by 199
Reynolds, G. P., Zhang, Z., & Zhang, X. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.677 · Cited by 198
Epigenetics and twins: three variations on the theme
PETRONIS, A. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.04.010 · Cited by 193
The GABA-glutamate connection in schizophrenia: which is the proximate cause?
Coyle, J. T. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.034 · Cited by 191
Interactions between the cytochrome P450 system and the second-generation antipsychotics
Prior, T. I., & Baker, G. B. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0312 · Cited by 188
Association between clozapine response and allelic variation in the 5-HT2C receptor gene
Sodhi, M. S., Arranz, M. J., Curtis, D., Ball, D. M., Sham, P., Roberts, G. W., Price, J., Collier, D. A., & Kerwin, R. W. (1995) · NeuroReport · doi:10.1097/00001756-199512000-00041 · Cited by 188
Self-citationMamo, D., Kapur, S., Shammi, C. M., Papatheodorou, G., Mann, S., Therrien, F., & Remington, G. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.818 · Cited by 188
Krebs, M. O., Guillin, O., Bourdel, M. C., Schwartz, J. C., Olie, J. P., Poirier, M. F., & Sokoloff, P. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000749 · Cited by 173
Laruelle, M. A., Frankle, W. G., Narendran, R., Kegeles, L. S., & Abi‐Dargham, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.017 · Cited by 172
Basile, V. S., Özdemir, V, Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., Kalow, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168
Qiu, J. (2006) · Nature · doi:10.1038/441143a · Cited by 166
Kirley, A., Lowe, N., Hawi, Z., Mullins, C., Daly, G., Waldman, I. D., McCarron, M., O'Donnell, D., Fitzgerald, M., & Gill, M. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20071 · Cited by 165
Tebartz van Elst, L., Valerius, G., Büchert, M., Thiel, T., Rüsch, N., Bubl, E., Hennig, J., Ebert, D., & Olbrich, H. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.041 · Cited by 164
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Kirchheiner, J., Fuhr, U., & Brockmöller, J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1801 · Cited by 160
MALDI-TOF Mass Spectrometry-Based Snp Genotyping
Pusch, W., Wurmbach, J.-H., Thiele, H., & Kostrzewa, M. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.4.537 · Cited by 158
Bipolar depression: pharmacotherapy and related therapeutic strategies
Thase, M. E., & Sachs, G. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00980-x · Cited by 158
Clozapine‐induced weight gain associated with the 5HT2C receptor −759C/T polymorphism
Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F., & Arndt, S. V. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30115 · Cited by 155
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
Segman, R. H., Heresco‐Levy, U., Finkel, B., Goltser‐Dubner, T., Shalem, R., Schlafman, M., Dorevitch, A., Yakir, A., Greenberg, D. A., Lerner, A., et al. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000842 · Cited by 155
Lencz, T., Robinson, D. G., Ke Xu, Ekholm, J. M., Sevy, S. M., Gunduz‐Bruce, H., Woerner, M. G., Kane, J. M., Goldman, D. A., & Malhotra, A. K. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.529 · Cited by 155
Segman, R. H., Neeman, T., Heresco‐Levy, U., Finkel, B., Karagichev, L., Schlafman, M., Dorevitch, A., Yakir, A., Lerner, A., Shelevoy, A., et al. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000511 · Cited by 153
Myers, R. L., Airey, D. C., Manier, D. H., Shelton, R. C., & Sanders‐Bush, E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.018 · Cited by 150
Abdolmaleky, H. M., Thiagalingam, S., & Wilcox, M. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505030-00002 · Cited by 149
Polymorphic Drug Oxidation: Relevance to the Treatment of Psychiatric Disorders
Bertilsson, L., & Dahl, M. (1996) · CNS Drugs · doi:10.2165/00023210-199605030-00006 · Cited by 149
Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine
Ellingrod, V. L., Perry, P. J., Ringold, J. C., Lund, B. C., Bever‐Stille, K., Fleming, F. W., Holman, T. L., & Miller, D. D. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20169 · Cited by 147
Risperidone-related Weight Gain: Genetic and Nongenetic Predictors
Lane, H., Liu, Y., Huang, C., Chang, Y., Wu, P.-L., Lu, C. ‐., & Chang, W. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203196.65710.2b · Cited by 147
Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD
Stein, M. A., Waldman, I. D., Sarampote, C. S., Seymour, K. E., Robb, A. S., Conlon, C. J., Kim, S., & Cook, E. H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300718 · Cited by 146
Bunney, W. E., Bunney, B. G., Vawter, M. P., Tomita, H., Li, J. Z., Evans, S. J., Choudary, P. V., Myers, R., Jones, E. G., Watson, S. J., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.657 · Cited by 145
Association of Risperidone Treatment Response With a Polymorphism in the 5-HT2A Receptor Gene
Lane, H., Chang, Y., Chiu, C., Chen, M., Hsieh, M.-H., & Chang, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1593 · Cited by 144
Hong, C., Yu, Y. W. ‐., Lin, C., & Tsai, S. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00828-0 · Cited by 144
The Evolution of Drug Metabolism
Nebert, D. W., & Dieter, M. Z. (2000) · Pharmacology · doi:10.1159/000028393 · Cited by 144
Risperidone plasma levels, clinical response and side–effects
Riedel, M. J., Schwarz, M., Strassnig, M., Spellmann, I., Müller–Arends, A., Weber, K., Zach, J., Müller, N., & Möller, H. ‐. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0556-4 · Cited by 143
Bakker, P. R., van Harten, P. N., & van Os, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.01.010 · Cited by 141
Metabolic drug interactions with new psychotropic agents
Spina, E., Scordo, M. G., & D’Arrigo, C. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00193.x · Cited by 139
Schäfer, M., Rujescu, D., Giegling, I., Guntermann, A., Erfurth, A., Bondy, B., & Möller, H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.802 · Cited by 138
Twin study of symptom dimensions in psychoses
Cardno, A. G., Sham, P. C., Murray, R. M., & McGuffin, P. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.1.39 · Cited by 138
Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
Arranz, M. J., Collier, D. A., Munro, J., Sham, P. C., Kirov, G., Sodhi, M., Roberts, G. W., Price, J., & Kerwin, R. W. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13094-9 · Cited by 136
Self-citationPozzi, L., Håkansson, K., Usiello, A., Borgkvist, A., Lindskog, M., Greengard, P., & Fisone, G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01851.x · Cited by 134
Duration of untreated psychosis predicts treatment outcome in an early psychosis program
Black, K., Peters, L., Rui, Q., Milliken, H., Whitehorn, D., & Kopala, L. C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00144-4 · Cited by 132
Reynolds, G. P., Yao, Z., Zhang, X., Sun, J., & Zhang, Z. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.001 · Cited by 132
−759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain
Tsai, S., Hong, C., Yu, Y. W. ‐., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11705-3 · Cited by 131
Weickert, T. W., Goldberg, T. E., Mishara, A. L., Apud, J. A., Kolachana, B. S., Egan, M. F., & Weinberger, D. R. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.012 · Cited by 130
Malhotra, A. K., Goldman, D. A., Ozaki, N., et al. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.8.1092 · Cited by 129
Joober, R., Benkelfat, C., Brisebois, K., Toulouse, A., Turecki, G., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Fortin, D., et al. (1999) · PubMed · Cited by 128
Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y., & Roth, B. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2017-1 · Cited by 128
Serotonin-6 receptor variant (C267T) and clinical response to clozapine
Yu, Y. W. ‐., Tsai, S., Lin, C., Hsu, C., Yang, K., & Hong, C. (1999) · Neuroreport · doi:10.1097/00001756-199904260-00014 · Cited by 126
Szekeres, G., Kéri, S., Juhász, A., Rimanóczy, Á., Szendi, I., Czimmer, C., & Janka, Z. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20045 · Cited by 126
Prakash, C., Kamel, A. M., Cui, D., Whalen, R., Miceli, J. J., & Tweedie, D. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00151.x · Cited by 125
Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity
Eap, C. B., Bender, S., Sirot, E. J., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., & Broly, F. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000116646.91923.2f · Cited by 125
Pharmacogenomics in schizophrenia: the quest for individualized therapy
Basile, V. S., Masellis, M., Potkin, S. G., & Kennedy, J. L. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2517 · Cited by 125
The Dosing of Atypical Antipsychotics
de León, J., Armstrong, S. C., & Cozza, K. L. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.3.262 · Cited by 124
Familial occurrence of tardive dyskinesia
Müller, D., Schulze, T. G., Knapp, M., Held, T., Krauss, H., Weber, T., Ahle, G., Maroldt, A., Alfter, D., Maier, W., et al. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00401.x · Cited by 123
New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Serretti, A., Ronchi, D. D., Lorenzi, C., & Berardi, D. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043456043 · Cited by 121
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor
Rietschel, M., Naber, D., Fimmers, R., et al. (1997) · Neuroreport · doi:10.1097/00001756-199705260-00040 · Cited by 119
Sharma, R. P., Rosen, C., Kartan, S., Guidotti, A., Costa, E., Grayson, D. R., & Chase, K. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.015 · Cited by 118
Lerer, B., Segman, R. H., Tan, E., Basile, V. S., Cavallaro, R., Aschauer, H. N., Strous, R. D., Chong, S. A., Heresco‐Levy, U., Verga, M., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005389 · Cited by 117
Glucuronidation enzymes, genes and psychiatry
de León, J. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003249 · Cited by 115
Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Smoking and Caffeine
de León, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.5.491 · Cited by 115
Reynolds, G. P., Arranz, B., Templeman, L. A., Fertuzinhos, S., & San, L. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1826 · Cited by 113
Altamura, A. C., Bassetti, R., Sassella, F., Salvadori, D., & Mundo, E. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00187-0 · Cited by 112
de León, J., Susce, M. T., Pan, R.-M., Koch, W. H., & Wedlund, P. J. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000177546.34799.af · Cited by 112
Genetic variation of the 5-HT2A receptor and response to clozapine
Nöthen, M. M., Rietschel, M., Erdmann, J., Oberländer, H., Möller, H., Naber, D., Propping, P., Burnet, P. W. J., & Harrison, P. J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92756-5 · Cited by 111
Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene
Flomen, R. H. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh536 · Cited by 111
Woodward, N. D., Jayathilake, K., & Meltzer, H. Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.002 · Cited by 109
McGavin, J. K., & Goa, K. L. (2002) · CNS Drugs · doi:10.2165/00023210-200216110-00008 · Cited by 109
Buckland, P. R., Hoogendoorn, B., Guy, C., Smith, S. K., Coleman, S. L., & O’Donovan, M. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.613 · Cited by 108
AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry
de León, J. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.6.3.277 · Cited by 107
Algorithms for large-scale genotyping microarrays
Liu, W., Di, X., Yang, G., Matsuzaki, H., Huang, J. H., Mei, R., Ryder, T. B., Webster, T. A., Dong, S., Liu, G., et al. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg332 · Cited by 106
−759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain
Basile, V. S., Masellis, M., Luca, V. D., Meltzer, H. Y., & Kennedy, J. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11706-5 · Cited by 105
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Bell, C., Nos, L., Fried, P., Pearce, D. A., Singh, S., Siderovski, D. P., Willard, F. S., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301002 · Cited by 104
Rietschel, M., Naber, D., Oberländer, H., Holzbach, R., Fimmers, R., Eggermann, K., Möller, H. J., Propping, P., & Nöthen, M. M. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00090-5 · Cited by 103
Lane, H., Lee, C.-C., Chang, Y., Lu, C. ‐., Huang, C.-H., & Chang, W. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004389 · Cited by 101
Özdemir, V., KALOW, W., Okey, A. B., Lam, M. S. M., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., & Roy, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00011 · Cited by 99
Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine
Fang, J., Coutts, R. T., McKenna, K. F., & Baker, G. B. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005298 · Cited by 99
Hwang, R., Shinkai, T., Luca, V. D., Müller, D. J., Ni, X., Macciardi, F. M., Potkin, S. G., Lieberman, J. A., Meltzer, H. Y., & Kennedy, J. L. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2223-5 · Cited by 98
Serotonin transporter gene (5-HTTLPR) and major psychoses
Serretti, A., Lilli, R., Lorenzi, C., Lattuada, E., Cusin, C., & Smeraldi, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000936 · Cited by 97
Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response
Birkett, J., Arranz, M. J., Munro, J., Osbourn, S., Kerwin, R. W., & Collier, D. A. (2000) · Neuroreport · doi:10.1097/00001756-200006260-00042 · Cited by 96
Self-citationKaiser, R., Tremblay, P.-B., Schmider, J., Henneken, M., Dettling, M., Müller-Oerlinghausen, B., Uebelhack, R., Roots, I., & Brockmöller, J. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000821 · Cited by 95
Kakihara, S., Yoshimura, R., Shinkai, K., Matsumoto, C., Goto, M., Kaji, K., Yamada, Y., Ueda, N., Ohmori, O., & Nakamura, J. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00002 · Cited by 95
Bondolfi, G., Morel, F., Crettol, S., Rachid, F., Baumann, P., & Eap, C. B. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000164609.14808.93 · Cited by 94
Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia
Arthur, H., Dahl, M., Siwers, B., & Sjöqvist, F. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00010 · Cited by 94
Kaiser, R., Tremblay, P.-B., Klufmöller, F., Roots, I., & Brockmöller, J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001054 · Cited by 93
Fehsel, K., Loeffler, S., Krieger, K., Henning, U., Agelink, M. W., Kolb-Bachofen, V., & Klimke, A. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000177668.42640.fe · Cited by 92
INFLUENCE OF PHARMACOGENETICS ON DRUG DISPOSITION AND RESPONSE
Eichelbaum, M. F., & Evert, B. O. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb01154.x · Cited by 91
Müller, D. J., Klempan, T., Luca, V. D., Sicard, T., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.037 · Cited by 91
Drug metabolism and atypical antipsychotics
Prior, T. I., Chue, P. S., Tibbo, P. G., & Baker, G. B. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00040-6 · Cited by 90
Pharmacogenomics of psychiatric disorders
Pickar, D., & Rubinow, K. B. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01603-5 · Cited by 89
Joober, R., Benkelfat, C., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Turecki, G., Rozen, R. R., & Rouleau, G. A. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000724 · Cited by 89
Masellis, M., Basile, V. S., Meltzer, H. Y., Lieberman, J. A., Sevy, S. M., Goldman, D. A., Hamblin, M. W., Macciardi, F. M., & Kennedy, J. L. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00016-5 · Cited by 89
Tiwari, A. K., Deshpande, S. N., Lerer, B., Nimgaonkar, V. L., & Thelma, B. K. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500415 · Cited by 87
Božina, N., Kuzman, M. R., Medved, V., Jovanović, N., Sertić, J., & Hotujac, L. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.002 · Cited by 87
Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055798 · Cited by 86
Antipsychotic drug treatment induces differential gene expression in the rat cortex
Kontkanen, O., Törönen, P., Lakso, M., Wong, G., & Ċastrén, E. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01213.x · Cited by 84
Theisen, F., Hinney, A., Brömel, T., Heinzel‐Gutenbrunner, M., Martin, M., Krieg, J.-C., Remschmidt, H., & Hebebrand, J. (2004) · Psychiatric Genetics · doi:10.1097/00041444-200409000-00003 · Cited by 83
Bishop, J. R., Ellingrod, V. L., Moline, J., & Miller, D. D. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.001 · Cited by 82
CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients
van Troostwijk, L. J. A. E. D., Koopmans, R. P., Vermeulen, H. D. B., & Guchelaar, H. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.09.010 · Cited by 82
Tarazi, F. I., Baldessarini, R. J., Kula, N. S., & Zhang, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052597 · Cited by 82
Cytochrome P4502D6 genotype does not determine response to clozapine.
Arranz, M. J., Dawson, E., Shaikh, S., Sham, P. C., Sharma, T., Aitchison, K. J., Crocq, M. A., Gill, M., Kerwin, R. W., & Collier, D. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04471.x · Cited by 81
Self-citationRubin, G. M. (2001) · Nature · doi:10.1038/35057277 · Cited by 81
Kaiser, R., Könneker, M., Henneken, M., Dettling, M., Müller-Oerlinghausen, B., Roots, I., & Brockmöller, J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000729 · Cited by 81
Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs
Theisen, F., Gebhardt, S., Haberhausen, M., Heinzel‐Gutenbrunner, M., Wehmeier, P. M., Krieg, J.-C., hnau, W. K., Schmidtke, J., Remschmidt, H., & Hebebrand, J. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00011 · Cited by 81
His452Tyr Polymorphism in the Human 5-HT2A Receptor Destabilizes the Signaling Conformation
Hazelwood, L. A., & Sanders‐Bush, E. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.5.1293 · Cited by 80
Polymorphisms of the dopamine D 4 receptor and response to antipsychotic drugs
Cohen, B. M., Ennulat, D. J., Centorrino, F., Matthysse, S., Konieczna, H., Chu, H.-M., & Cherkerzian, S. (1999) · Psychopharmacology · doi:10.1007/s002130050799 · Cited by 80
Genetic basis of toxic reactions to drugs and chemicals
Cascorbi, I. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.10.015 · Cited by 80
Wang, Y.-C., Bai, Y., Chen, J., Lin, C.-C., Lai, I., & Liou, Y. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000175600.26893.fa · Cited by 80
Suzuki, A., Kondo, T., Otani, K., Mihara, K., Yasui-Furukori, N., Sano, A., Koshiro, K., & Kaneko, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1714 · Cited by 80
Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat
MacDonald, M. L., Eaton, M. E., Dudman, J. T., & Konradi, C. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.022 · Cited by 79
Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
Hwu, H., Hong, C., Lee, Y.-L., Lee, P.-C., & Lee, S. F. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00134-6 · Cited by 78
A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers
de Leon, J., Diaz, F. J., Rogers, T., Browne, D., Dinsmore, L., Ghosheh, O. H., Dwoskin, L. P., & Crooks, P. A. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00348-2 · Cited by 77
Self-citationTiwari, A. K., Deshpande, S. N., Rao, A. R., Triptish Bhatia, A., Lerer, B., Nimgaonkar, V. L., & Thelma, B. K. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.011 · Cited by 77
Dopamine D3 Receptor Ser9Gly Polymorphism and Risperidone Response
Lane, H., Hsu, S.-K., Liu, Y., Chang, Y., Huang, C.-H., & Chang, W. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150226.84371.76 · Cited by 76
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo, M. G., Spina, E., Romeo, P., Dahl, M. L., Bertilsson, L., Johansson, I., & Sjöqvist, F. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000222 · Cited by 76
Zhang, Z.-J., Zhang, X.-B., Sha, W.-W., Zhang, X.-B., & Reynolds, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001052 · Cited by 75
Park, Y., Chung, Y.-C., Lee, S., Lee, K., Kim, H., Byun, Y., Lim, S., Paik, J., & Lee, H. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30311 · Cited by 75
Tsai, S., Hong, C., Yu, Y. W. ‐., Lin, C., Song, H., Lai, H., & Yang, K. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00170-x · Cited by 75
Turbay, D., Lieberman, J. A., Alper, C. A., et al. (1997) · Blood · doi:10.1182/blood.v89.11.4167 · Cited by 74
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
Ruaño, G., Goethe, J. W., Caley, C. F., Woolley, S. B., Holford, T. R., Kocherla, M., Windemuth, A., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001944 · Cited by 74
Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia
Bruneau, E., McCullumsmith, R. E., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.012 · Cited by 73
Dettling, M., Cascorbi, I., Roots, I., & Müller-Oerlinghausen, B. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.1.93 · Cited by 72
Wu, S., Xing, Q., Gao, R., Li, X., Gu, N., Feng, G., & He, L. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.014 · Cited by 72
5HT2a receptor T102C polymorphism and schizophrenia
Clifford, C., Nunez, D. R., Malhotra, A. K., Goldman, D. A., Buchanan, R., Breier, A. F., Pickar, D., Jönsson, E. G., Nöthen, M. M., Bunzel, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91650-5 · Cited by 72
Self-citationLiou, Y., Liao, D., Chen, J., Wang, Y.-C., Lin, C.-C., Bai, Y., Yu, S.-C., Lin, M., & Lai, I. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:3:243 · Cited by 71
Wehmeier, P. M., Gebhardt, S., Schmidtke, J., Remschmidt, H., Hebebrand, J., & Theisen, F. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.02.018 · Cited by 71
Lane, H. C., 林政傑;Lin, C.-C., Huang, C.-H., Chang, Y.-C., Hsu, S.-K., & Chang, W.-H. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.08.006 · Cited by 70
CYP2D6 polymorphisms and atypical antipsychotic weight gain
Ellingrod, V. L., Miller, D. D., Schultz, S. K., Wehring, H. J., & Arndt, S. V. (2002) · Psychiatric Genetics · doi:10.1097/00041444-200203000-00008 · Cited by 70
Genetic variants of the serotonin system and weight change during clozapine treatment
Hong, C., Lin, C., Yu, Y. W. ‐., Yang, K., & Tsai, S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00010 · Cited by 69
Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms
Casey, D. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900026651 · Cited by 69
Monozygotic twins concordant for response to clozapine
Vojvoda, D., Grimmell, K., Sernyak, M. J., & Mazure, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91594-9 · Cited by 68
Suzuki, A., Kondo, T., Mihara, K., Yasui‐Furukori, N., Ishida, M., Furukori, H., Kaneko, S., Inoue, Y., & Otani, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200108000-00009 · Cited by 68
5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine
Travis, M. J., Busatto, G. F., Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Gacinovic, S., Mertens, J. J. R., Terriere, D., Costa, D. C., Ell, P. J., et al. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.173.3.236 · Cited by 68
Chagnon, Y. C., Mérette, C., Bouchard, R.-H., Émond, C., Roy, M.-A., & Maziade, M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001537 · Cited by 67
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Roh, H., Kim, C. E., Chung, W., Park, C., Svensson, J., & Bertilsson, L. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100372 · Cited by 67
Nothnagel, M., & Rohde, K. (2005) · The American Journal of Human Genetics · doi:10.1086/498175 · Cited by 67
Schulze, T. G., Schumacher, J. H., Müller, D. J., Krauß, H., Alfter, D., Maroldt, A., Ahle, G., Maroldt, A., y Fernández, A. N., Weber, T., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1472 · Cited by 66
Cited by
van Os, J., Rutten, B. P., & Poulton, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn117 · Cited by 713
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
ROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 307
Metadata
- Authors
- Arranz, M. J., & de Leon, J.
- Venue
- Molecular Psychiatry
- Published
- 2007-06-05
- Volume
- 12
- Issue
- 8
- Pages
- 707-747
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2094769668
- Cited by
- 351
- References
- 281
- FWCI
- 39.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.